Disease Reactivation After Cessation of Disease-Modifying Therapy in Patients With Relapsing-Remitting Multiple Sclerosis. (25th October 2022)

• Record Type: Journal Article
• Authors: Roos, Izanne; Malpas, Charles; Leray, Emmanuelle; Casey, Romain; Horakova, Dana; Havrdova, Eva Kubala; Debouverie, Marc; Patti, Francesco; De Seze, Jerome; Izquierdo, Guillermo; Eichau, Sara; Edan, Gilles; Prat, Alexandre; Girard, Marc; Ozakbas, Serkan; Grammond, Pierre; Zephir, Helene; Ciron, Jonathan; Maillart, Elisabeth; Moreau, Thibault; Amato, Maria Pia; Labauge, Pierre; Alroughani, Raed; Buzzard, Katherine; Skibina, Olga; Terzi, Murat; Laplaud, David Axel; Berger, Eric; Grand'Maison, Francois; Lebrun-Frenay, Christine; Cartechini, Elisabetta; Boz, Cavit; Lechner-Scott, Jeannette; Clavelou, Pierre; Stankoff, Bruno; Prevost, Julie; Kappos, Ludwig; Pelletier, Jean; Shaygannejad, Vahid; Yamout, Bassem I.; Khoury, Samia J.; Gerlach, Oliver; Spitaleri, Daniele L.A.; Van Pesch, Vincent; Gout, Olivier; Turkoglu, Recai; Heinzlef, Olivier; Thouvenot, Eric; McCombe, Pamela Ann; Soysal, Aysun; Bourre, Bertrand; Slee, Mark; Castillo-Trivino, Tamara; Bakchine, Serge; Ampapa, Radek; Butler, Ernest Gerard; Wahab, Abir; Macdonell, Richard A.; Aguera-Morales, Eduardo; Cabre, Philippe; Ben, Nasr Haifa; Van der Walt, Anneke; Laureys, Guy; Van Hijfte, Liesbeth; Ramo-Tello, Cristina M.; Maubeuge, Nicolas; Hodgkinson, Suzanne; Sánchez-Menoyo, José Luis; Barnett, Michael H.; Labeyrie, Celine; Vucic, Steve; Sidhom, Youssef; Gouider, Riadh; Csepany, Tunde; Sotoca, Javier; de Gans, Koen; Al-Asmi, Abdullah; Fragoso, Yara Dadalti; Vukusic, Sandra; Butzkueven, Helmut; Kalincik, Tomas;
• Is Part Of: Neurology. Volume 99:Number 17(2022)
• Page Start: e1926
• Page End: e1944
• Publication Date: 2022-10-25
• Subjects: Neurology -- Periodicals; Neurology -- Periodicals; Neurologie -- Périodiques; 616.8
• DOI: 10.1212/WNL.0000000000201029
• Languages: English
• ISSNs: 0028-3878

Abstract

Abstract : Background and Objectives: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. Methods: This was a retrospective cohort study from 2 large observational MS registries: MSBase and OFSEP. Patients with relapsing-remitting MS who had ceased a disease-modifying therapy and were followed up for the subsequent 12 months were included in the analysis. The primary study outcome was annualized relapse rate in the 12 months after disease-modifying therapy discontinuation stratified by patients who did, and did not, commence a subsequent therapy. The secondary endpoint was the predictors of first relapse and disability accumulation after treatment discontinuation. Results: A total of 14, 213 patients, with 18, 029 eligible treatment discontinuation epochs, were identified for 7 therapies. Annualized rates of relapse (ARRs) started to increase 2 months after natalizumab cessation (month 2-4 ARR 0.47, 95% CI 0.43–0.51). Commencement of a subsequent therapy within 2-4 months reduced the magnitude of disease reactivation (mean ARR difference: 0.15, 0.08–0.22). After discontinuation of fingolimod, rates of relapse increased overall (month 1–2 ARR: 0.80, 0.70–0.89) and stabilized faster in patients who started a new therapy within 1-2 months (mean ARR difference: 0.14, −0.01 to 0.29). The magnitude of disease reactivation for other therapies was low but reduced further by commencement of another treatment 1–10 months after treatment discontinuation. Predictors of relapse were a higher relapse rate in the year before cessation, female sex, younger age, and higher EDSS score. Commencement of a subsequent therapy reduced both the risk of relapse (HR 0.76, 95% CI 0.72–0.81) and disability accumulation (0.73, 0.65–0.80). Discussion: The rate of disease reactivation after treatment cessation differs among MS treatments, with the peaks of relapse activity ranging from 1 to 10 months in untreated cohorts that discontinued different therapies. These results suggest that untreated intervals should be minimized after stopping antitrafficking therapies (natalizumab and fingolimod). Classification of Evidence: This study provides Class III that disease reactivation occurs within months of discontinuation of MS disease-modifying therapies. The risk of disease activity is reduced by commencement of a subsequent therapy.